Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 7 Genitourinary 2 Tumor-Agnostic 1 Thoracic 1 Dermatologic 1

Conditions

Interventions

pembrolizumab 81 Nivolumab 55 Ipilimumab 44 Cyclophosphamide 38 aldesleukin 26 Interleukin-2 25 fludarabine 17 Temozolomide 17 fludarabine phosphate 16 trametinib 11 dabrafenib 11 Radiotherapy 11 Biopsy 11 avelumab 10 Paclitaxel 9 spartalizumab 8 cemiplimab 8 Dacarbazine 8 Cisplatin 8 Bevacizumab 8 sargramostim 7 binimetinib 7 Fluorouracil 7 poly ICLC 6 lenvatinib 6 epacadostat 6 atezolizumab 6 Magnetic Resonance Spectroscopy 6 Granulocyte-Macrophage Colony-Stimulating Factor 6 montanide ISA 51 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Electroporation × Dermatologic × Clear all

NCT01764009 2015-09-11

AIMM

Valerio Therapeutics

Phase 1/2 Withdrawn

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡